Stock Analysis
- Canada
- /
- Medical Equipment
- /
- TSXV:ZEN
Zentek Full Year 2024 Earnings: CA$0.12 loss per share (vs CA$0.14 loss in FY 2023)
Zentek (CVE:ZEN) Full Year 2024 Results
Key Financial Results
- Net loss: CA$11.7m (loss narrowed by 19% from FY 2023).
- CA$0.12 loss per share (improved from CA$0.14 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zentek shares are down 3.5% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for Zentek that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Zentek is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're helping make it simple.
Find out whether Zentek is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSXV:ZEN
Zentek
Engages in the research and development of graphene and related nanomaterials in Canada.
Mediocre balance sheet and overvalued.